Home>
US Stocks>
Esperion Therapeutics

Esperion Therapeutics share price today

(ESPR)

Esperion Therapeutics share price is $2.19 & ₹186.10 as on 21 Dec 2024, 2.30 'hrs' IST

$2.19

▲

0.02

(0.69%)

Market is closed - opens 8 PM, 23 Dec 2024

View live Esperion Therapeutics share price in Dollar and Rupees. Guide to invest in Esperion Therapeutics from India. Also see the sentimental analysis on Indian investors investing in Esperion Therapeutics. Get details on the Indian mutual funds that are investing in Esperion Therapeutics. Get Analyst recommendations and forecasts along with all the Esperion Therapeutics's financials.

Esperion Therapeutics share price movements

Today's Low: $2.15
Today's High: $2.23
$2.19
2.05%
Downside
Day's Volatility :3.81%
Upside
1.79%
52 Weeks Low: $1.58
52 Weeks High: $3.94
$2.19
27.85%
Downside
52 Weeks Volatility :59.9%
Upside
44.42%

Esperion Therapeutics Returns

Period	Esperion Therapeutics, Inc.	Sector (Health Care)	Index (Russel 2000)
3 Months	33.44%	-12.2%	0.0%
6 Months	-0.23%	-6.9%	0.0%
1 Year	-7.84%	2.7%	0.0%
3 Years	-57.77%	-0.2%	-17.3%

Esperion Therapeutics Key Statistics

in dollars & INR

Previous Close	$2.175
Open	$2.15
Today's High	$2.23
Today's Low	$2.145
Market Capitalization	$425.6M
Today's Volume	$3.6M
52 Week High	$3.94
52 Week Low	$1.58
Revenue TTM	$295.5M
EBITDA	$16.5M
Earnings Per Share (EPS)	$-0.67
Profit Margin	-29.37%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-260.79%

How to invest in Esperion Therapeutics from India?

It is very easy for Indian residents to invest directly in Esperion Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Esperion Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Esperion Therapeutics or ESPR on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Esperion Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Esperion Therapeutics shares which would translate to 0.388 fractional shares of Esperion Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India , including recognised companies like Esperion Therapeutics, in just a few clicks!

Returns in Esperion Therapeutics for Indian investors in Rupees

Investment Value

₹1,00,000

Esperion Therapeutics investment value today

Current value as on today

₹1,09,299

Returns

₹9,299

(+9.3%)

Returns from Esperion Therapeutics Stock

₹7,203 (false-7.2%)

Dollar Returns

₹2,095 (+2.1%)

Indian investors sentiment towards Esperion Therapeutics

61%

Period: Sep 21, 2024 to Dec 20, 2024. Change in 30 Days versus previous period

Search volume for Esperion Therapeutics on INDmoney from India has grown in the last 30 days as on Dec 21, 2024. 61% more investors are searching Esperion Therapeutics in the last 30 days versus the previous period.

Global Institutional Holdings in Esperion Therapeutics

Wasatch Advisors LP
11.85%
BlackRock Inc
7.10%
Vanguard Group Inc
6.62%
Bellevue Group AG
5.05%
Two Seas Capital LP
3.34%
Great Point Partners LLC
2.94%

Analyst Recommendation on Esperion Therapeutics

Buy

71%Buy

28%Hold

0%Sell

Based on 14 Wall street analysts offering stock ratings for Esperion Therapeutics(by analysts ranked 0 to 5 stars)

Based on 14 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Esperion Therapeutics

What analysts predicted

Upside of 242.84%

Current:

$2.19

Target:

$7.51

Insights on Esperion Therapeutics

Price Movement
In the last 3 months, ESPR stock has moved up by 29.5%
Decreasing Revenue
Revenue is down for the last 3 quarters, 137.73M → 51.63M (in $), with an average decrease of 38.2% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -61.92M → -29.52M (in $), with an average increase of 109.7% per quarter
ESPR vs HLN (1 yr)
In the last 1 year, Haleon Plc Spon Ads has given 19.9% return, outperforming this stock by 24.1%
Price to Sales
ForESPR every $1 of sales, investors are willing to pay $1.2, whereas for Haleon Plc Spon Ads, the investors are paying $4.0 for every $1 of sales.

Esperion Therapeutics Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$184.5M	-
Net Income	$-201.8M	↑ 20.85%
Net Profit Margin	-109.4%	-

	FY19	Y/Y Change
Revenue	$148.4M	↓ 19.57%
Net Income	$-109.0M	↓ 45.98%
Net Profit Margin	-73.48%	↑ 35.92%

	FY20	Y/Y Change
Revenue	$227.5M	↑ 53.37%
Net Income	$-166.2M	↑ 52.44%
Net Profit Margin	-73.04%	↑ 0.44%

	FY21	Y/Y Change
Revenue	$78.4M	↓ 65.52%
Net Income	$-318.8M	↑ 91.84%
Net Profit Margin	-406.42%	↓ 333.38%

	FY22	Y/Y Change
Revenue	$75.5M	↓ 3.79%
Net Income	$-287.8M	↓ 9.73%
Net Profit Margin	-381.34%	↑ 25.08%

	FY23	Y/Y Change
Revenue	$116.3M	↑ 54.14%
Net Income	$-209.2M	↓ 27.3%
Net Profit Margin	-179.87%	↑ 201.47%

	Q2 FY23	Q/Q Change
Revenue	$25.8M	↑ 5.99%
Net Income	$-49.9M	↓ 44.03%
Net Profit Margin	-193.65%	↑ 173.07%

	Q3 FY23	Q/Q Change
Revenue	$34.0M	↑ 31.73%
Net Income	$-41.3M	↓ 17.39%
Net Profit Margin	-121.43%	↑ 72.22%

	Q4 FY23	Q/Q Change
Revenue	$32.3M	↓ 5.06%
Net Income	$-56.3M	↑ 36.59%
Net Profit Margin	-174.71%	↓ 53.28%

	Q1 FY24	Q/Q Change
Revenue	$137.7M	↑ 327.09%
Net Income	$61.0M	↓ 208.3%
Net Profit Margin	44.3%	↑ 219.01%

	Q2 FY24	Q/Q Change
Revenue	$73.8M	↓ 46.39%
Net Income	$-61.9M	↓ 201.48%
Net Profit Margin	-83.87%	↓ 128.17%

	Q3 FY24	Q/Q Change
Revenue	$51.6M	↓ 30.07%
Net Income	$-29.5M	↓ 52.32%
Net Profit Margin	-57.18%	↑ 26.69%

	FY18	Y/Y Change
Profit	$184.5M	↓ 224.98%

	FY19	Y/Y Change
Profit	$-27.2M	↓ 114.77%

	FY20	Y/Y Change
Profit	$225.2M	↓ 926.35%

	FY21	Y/Y Change
Profit	$64.2M	↓ 71.47%

	FY22	Y/Y Change
Profit	$48.5M	↓ 24.48%

	FY23	Y/Y Change
Profit	$73.1M	↑ 50.63%

	Q2 FY23	Q/Q Change
Profit	$19.0M	↑ 49.88%

	Q3 FY23	Q/Q Change
Profit	$20.6M	↑ 8.38%

	Q4 FY23	Q/Q Change
Profit	$20.8M	↑ 0.97%

	Q1 FY24	Q/Q Change
Profit	$127.7M	↑ 513.99%

	Q2 FY24	Q/Q Change
Profit	$58.2M	↓ 54.4%

	Q3 FY24	Q/Q Change
Profit	$34.3M	↓ 41.0%

	FY18	Y/Y Change
Operating Cash Flow	$-148.6M	↑ 13.2%
Investing Cash Flow	$140.4M	↓ 491.74%
Financing Cash Flow	$10.7M	↓ 93.46%

	FY19	Y/Y Change
Operating Cash Flow	$-70.3M	↓ 52.68%
Investing Cash Flow	$64.2M	↓ 54.27%
Financing Cash Flow	$136.2M	↑ 1173.56%

	FY20	Y/Y Change
Operating Cash Flow	$-85.2M	↑ 21.09%
Investing Cash Flow	$21.4M	↓ 66.75%
Financing Cash Flow	$201.7M	↑ 48.11%

	FY21	Y/Y Change
Operating Cash Flow	$-263.8M	↑ 209.72%
Investing Cash Flow	$-50.5M	↓ 336.39%
Financing Cash Flow	$268.2M	↑ 32.96%

	FY22	Y/Y Change
Operating Cash Flow	$-174.8M	↓ 33.73%
Investing Cash Flow	$8.1M	↓ 116.05%
Financing Cash Flow	$32.6M	↓ 87.84%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-24.8M	↓ 54.47%
Investing Cash Flow	$17.5M	↓ 30.0%
Financing Cash Flow	$809.0K	↓ 98.37%

Esperion Therapeutics Technicals Summary

Sell

Neutral

Buy

Esperion Therapeutics is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Esperion Therapeutics Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Esperion Therapeutics, Inc.	-9.75%	-0.23%	-7.84%	-57.77%	-96.1%
Neurocrine Biosciences Inc.	9.47%	1.0%	5.07%	58.94%	24.49%
Haleon Plc Spon Ads	2.32%	12.27%	19.02%	30.9%	30.9%
Zoetis Inc.	-6.92%	-4.84%	-16.13%	-32.31%	23.53%
Viatris Inc.	-7.62%	15.85%	13.9%	-8.45%	-25.76%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Esperion Therapeutics, Inc.	NA	NA	-4.78	-0.29	-2.61	0.04	NA	-1.89
Neurocrine Biosciences Inc.	35.99	35.99	0.32	6.54	0.16	0.12	NA	26.87
Haleon Plc Spon Ads	28.56	28.56	1.73	0.34	0.07	0.04	0.02	1.82
Zoetis Inc.	31.33	31.33	2.6	5.88	0.47	0.15	0.01	11.59
Viatris Inc.	224.4	NA	0.07	2.69	-0.04	0.02	0.04	16.58

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Esperion Therapeutics, Inc.	Buy	$425.6M	-96.1%	NA	-29.37%
Neurocrine Biosciences Inc.	Buy	$13.7B	24.49%	35.99	17.21%
Haleon Plc Spon Ads	Buy	$44.2B	30.9%	28.56	10.75%
Zoetis Inc.	Buy	$75.3B	23.53%	31.33	26.55%
Viatris Inc.	Hold	$14.6B	-25.76%	224.4	-5.87%

About Esperion Therapeutics

esperion therapeutics, inc. is a pharmaceutical company focused on developing and commercializing first-in-class, oral, ldl-c lowering therapies for the treatment of patients with hypercholesterolemia. etc-1002, the company's lead product candidate, is an inhibitor of atp citrate lyase, a well-characterized enzyme on the cholesterol biosynthesis pathway; the same pathway that includes hmg-coa reductase, the enzyme target of statins. the company has successfully completed its phase 1 and phase 2 development programs for etc-1002, and plans to initiate its etc-1002 phase 3 development program by the end of 2015. for more information, please visit www.esperion.com.

Organization	Esperion Therapeutics
Employees	240
CEO	Mr. Sheldon L. Koenig
Industry	Health Technology

Management People of Esperion Therapeutics

Name	Title
Mr. Sheldon L. Koenig	President, CEO & Director
Mr. Eric J. Warren R.Ph.	Chief Commercial Officer
Mr. Benjamin Halladay M.B.A.	Chief Financial Officer
Mr. Glenn P. Brame	Chief Technical Operations Officer
Mr. Benjamin O. Looker J.D.	General Counsel & Corporate Secretary
Tiffany Aldrich M.B.A.	Associate Director of Corporate Communications
Ms. Betty Jean Swartz	Chief Business Officer

Important FAQs about investing in Esperion Therapeutics from India :

What is Esperion Therapeutics share price today?

Esperion Therapeutics share price today stands at $2.19, Open: $2.15 ; Previous Close: $2.17 ; High: $2.23 ; Low: $2.15 ; 52 Week High: $3.94 ; 52 Week Low: $1.58. The stock opens at $2.15, after a previous close of $2.17. The stock reached a daily high of $2.23 and a low of $2.15, with a 52-week high of $3.94 and a 52-week low of $1.58.

Can Indians buy Esperion Therapeutics shares?

Yes, Indians can invest in the Esperion Therapeutics (ESPR) from India.

With INDmoney, you can buy Esperion Therapeutics at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Esperion Therapeutics at zero transaction cost.

How can I buy Esperion Therapeutics shares from India?

It is very easy to buy Esperion Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Esperion Therapeutics be purchased?

Yes, you can buy fractional shares of Esperion Therapeutics with INDmoney app.

What are the documents required to start investing in Esperion Therapeutics stocks?

To start investing in Esperion Therapeutics, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.